Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors (NCT04429542)

🧪 Interventions in This Study

• BCA101 (DRUG)
• Pembrolizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (20 Sites)

• Moores Cancer Center UC San Diego Health — La Jolla, California
• Keck School of Medicine of USC — Los Angeles, California
• UCLA — Los Angeles, California
• University of California, Davis Comprehensive Cancer Center — Sacramento, California
• H. Lee Moffitt Cancer Center and Research Institute, Inc — Tampa, Florida
• Dana Farber/Partners Cancer Care Inc — Boston, Massachusetts
• Memorial Sloan Kettering — New York, New York
• Columbia University Herbert Irving Comprehensive Cancer Center — New York, New York
• Levine Cancer Institute — Charlotte, North Carolina
• Cleveland Clinic — Cleveland, Ohio
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
• Rhode Island Hospital — Providence, Rhode Island
• Medical University of South Carolina, Hollings Cancer Center — Charleston, South Carolina
• Vanderbilt University Medical Center — Nashville, Tennessee
• MD Anderson Cancer Center — Houston, Texas
• Chris O'Brien Lifehouse — Camperdown, New South Wales
• Calvary Mater Newcastle — Waratah, New South Wales
• Austin Hospital — Heidelberg, Victoria
• Peter MacCallum Cancer Centre — Melbourne, Victoria
• Princess Margaret Cancer Centre — Toronto, Ontario

📞 Contact the Study Coordinator

Phone: (617) 800-0335

Email: info@bicara.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Head and Neck Squamous Cell Carcinoma

• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Fullerton, California
• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck — Duarte, California
• MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients — Gilbert, Arizona
• Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 — St Louis, Missouri
• Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial — Buffalo, New York
• Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca — Baltimore, Maryland

Explore by condition: All Head and Neck Squamous Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.